KarXT (xanomeline-trospium) is the lead candidate in our pipeline, currently being evaluated in Phase 3 clinical trials as both a monotherapy and adjunctive therapy for the treatment of schizophrenia, as well as for the treatment of psychosis in Alzheimer’s disease. KarXT represents a major advancement in harnessing the potential of muscarinic receptors and, through its novel mechanism of action, could provide a new approach to treating psychiatric and neurological conditions.

KarXT mechanism of action